Enhanced Investments - Financial Portal

Notification of transactions by persons discharging managerial responsibilities and persons closely associated

Published: 2022-12-06 17:30:27 ET

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(‘Mediclinic’, or the ‘Company’, or the ‘Group’)

6 December 2022

        NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
           RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

  1.       Details of persons discharging managerial responsibilities (‘PDMR’) / persons closely
           associated with them (‘PCA’)

  a)       Name                     Koert Pretorius

  2.       Reason for the notification

  a)       Position / status        Group Chief Operating Officer – Mediclinic International plc

  b)       Initial notification /   Initial notification
           amendment
  3.       Details of the issuer, emission allowance market participant, auction platform, auctioneer or
           auction monitor

  a)       Name                     Mediclinic International plc

  b)       LEI                      2138002S5BSBIZTD5I60

  4.       Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
           type of transaction; (iii) each date; and (iv) each place where transactions have been
           conducted

  a)       Description of the       Ordinary shares
           financial instrument

           Identification Code      GB00B8HX8Z88

  b)       Nature of the            Sale of shares
           transaction

  c)       Price(s) and
           volume(s)                 Price(s)                           Volume(s)
                                     ZAR 104.21                         75 000


  d)       Aggregated
           information

           Aggregated volume        75 000

           Price                    ZAR 104.21 per share
  e)        Date of the                  5 December 2022
            transaction

  f)        Place of the                 Johannesburg Stock Exchange
            transaction




ABOUT MEDICLINIC INTERNATIONAL PLC

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with
divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in
such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by
patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 30 September 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, three mental health facilities,
21 day case clinics and 23 outpatient clinics. Hirslanden operated 17 hospitals and five day case clinics in
Switzerland with around 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three
of which in Namibia), five subacute hospitals, three mental health facilities and 14 day case clinics (four of which
operated by Intercare) across South Africa, and around 8 700 inpatient beds; and Mediclinic Middle East operated
seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In
addition, under management contract Mediclinic Middle East will open a 200-bed hospital in the Kingdom of Saudi
Arabia in 2023.

The Company’s primary listing is on the London Stock Exchange (‘LSE’) in the United Kingdom, with secondary
listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% (2022: 29.9%) interest in Spire Healthcare Group plc, a leading private healthcare
group based in the United Kingdom and listed on the LSE.

CONTACT INFORMATION
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Enhanced Investments, Inc.
329 South Oyster Bay Road #2085
Plainview, NY 11803
team@eninvs.com

Important disclosures

Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.

Nothing on this website should be considered an offer, solicitation of an offer, or advice to buy or sell securities.
Past performance is no guarantee of future results. Any historical returns, expected returns [or probability projections] are hypothetical in nature and may not reflect actual future performance.
All the strategies assume investments in equity invstrumenta only and are more relevant for "agressive investment profile". Eastern European flagship strategy assumes using up to 20% leverage of total portfolio. GlobalCommodities and US Growth strategy currently assume no leverage.
Results for the Enhanced Investments strategies as compared to the performance of Illustrative Benchmarks is for informational purposes only. Our investment program does not mirror that of the Illustrative Benchmarks and the volatility may be materially different from the volatility of Illustrative Benchmarks. Reference or comparison to an Illustrative Benchmark does not imply that strategies of Enhanced Investments will be constructed in the same way as the Illustrative Benchmark or achieve returns, volatility, or other results similar to those of the Illustrative Benchmark. The S&P 500 is an unmanaged market capitalization-weighted index of 500 common stocks chosen for market size, liquidity, and industry group representation to represent U.S. equity performance.
Performance results were prepared by Enhanced Investments, and have not been compiled, reviewed or audited by an independent accountant. Performance estimates are subject to future adjustment and revision. Investors should be aware that a loss of investment is possible. Account holdings are for illustrative purposes only and are not investment recommendations. Additional information, including (i) the calculation methodology; and (ii) a list showing the contribution of each holding to the portfolio’s performance during the time period will be provided upon request.
All statements made via social media sites sponsored or maintained by Enhanced Investments and its affiliates are for informational purposes only and do not constitute a comprehensive description of Enhanced Investments' investment advisory services.
Certain investments are not suitable for all investors. Before investing, consider your investment objectives and applicable fees. The rate of return on investments can vary widely over time, especially for long term investments. Investment losses are possible, including the potential loss of all amounts invested. Information provided by Enhanced Investments is for informational and general educational purposes only and is not investment or financial advice.